{"organizations": [], "uuid": "a90e8b9e2b58b995e3995cf22da33f1ffe8c4e19", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180209.html", "section_title": "Archive News &amp; Video for Friday, 09 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-symbio-pharmaceuticals-says-termin/brief-symbio-pharmaceuticals-says-termination-of-development-of-patient-controlled-pain-management-drug-syb-p-1501-idUSL4N1PZ366", "country": "US", "domain_rank": 408, "title": "BRIEF-SymBio Pharmaceuticals says termination of development of patient-controlled pain management drug SyB P-1501", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.855, "site_type": "news", "published": "2018-02-09T16:06:00.000+02:00", "replies_count": 0, "uuid": "a90e8b9e2b58b995e3995cf22da33f1ffe8c4e19"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-symbio-pharmaceuticals-says-termin/brief-symbio-pharmaceuticals-says-termination-of-development-of-patient-controlled-pain-management-drug-syb-p-1501-idUSL4N1PZ366", "ord_in_thread": 0, "title": "BRIEF-SymBio Pharmaceuticals says termination of development of patient-controlled pain management drug SyB P-1501", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "symbio pharmaceuticals ltd", "sentiment": "negative"}, {"name": "brief-symbio pharmaceuticals", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 9 (Reuters) - SymBio Pharmaceuticals Ltd\n* Says it terminates the development of “IONSYS” or “SyB P-1501” in Japan, a drug for patient-controlled, short-term management of acute postoperative pain during hospitalization\nSource text in Japanese: goo.gl/ikDcFw\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/ikDcFw"], "published": "2018-02-09T16:06:00.000+02:00", "crawled": "2018-02-10T14:03:42.003+02:00", "highlightTitle": ""}